Discovery of a potent dual ALK and EGFR T790M inhibitor
- 1 August 2017
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 136, 497-510
Abstract
No abstract availableKeywords
Funding Information
- Daegu-Gyeongbuk Medical Innovation Foundation New Drug Development Center R&D Project (DG15C011)
This publication has 35 references indexed in Scilit:
- Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung AdenocarcinomaJournal of Clinical Oncology, 2015
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution MutationsThe Oncologist, 2014
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLCCancer Discovery, 2013
- Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesJournal of Medicinal Chemistry, 2013
- Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family BlockerThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Discovery of selective irreversible inhibitors for EGFR-T790MBioorganic & Medicinal Chemistry Letters, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Ba/F3 cells and their use in kinase drug discoveryCurrent Opinion in Oncology, 2007